Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model
- Conditions
- Interventions
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 45
- Registration Number
- NCT03284931
- Locations
- 🇺🇸
Sage Investigational Site, New York, New York, United States
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 67
- Registration Number
- NCT03283371
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT03224793
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 263
- Registration Number
- NCT03222973
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT03177083
- Locations
- 🇵🇹
Hospital Fernando Fonseca, Amadora, Portugal
🇵🇹Hospital Evora, Evora, Portugal
🇵🇹Hospital de Braga, Braga, Portugal
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 50
- Registration Number
- NCT03116113
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 585
- Registration Number
- NCT03100734
- Locations
- 🇩🇪
Research Site, München, Bavaria, Germany
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 506
- Registration Number
- NCT03093324
- Locations
- 🇵🇱
Alkermes Investigational Site, Szczecin, Poland
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy
- Conditions
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 23
- Registration Number
- NCT03091569
- Locations
- 🇮🇹
Research Site, Napoli, Italy
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
- Conditions
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT03088956
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States